EURONEXT:MDMA
Pharmala Biotech Holdings Inc.
- Stock
Last Close
0.11
26/07 13:55
Volume Today
15.54K
Avg: 2.03M
PE Ratio
−61.79
PFCF: −36.83
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
May '21 | Nov '21 | Feb '22 | May '22 | Aug '22 | Nov '22 | Feb '23 | May '23 | Aug '23 | Nov '23 | Feb '24 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue | 70.52K - | 7.55K 89.30% | 93.33K - | 438.67K - | 752.47K 71.54% | 90.42K 87.98% | ||||||
cost of revenue | 1.85K - | 434 76.59% | 13.18K 2,936.41% | 13.18K 0% | 13.18K 0% | 77.90K 491.17% | 292.96K 276.05% | 15.78K 94.61% | ||||
gross profit | 68.67K - | 7.11K 89.64% | -13.18K 285.27% | 80.16K 708.26% | -13.18K 116.44% | 360.76K 2,837.62% | 459.51K 27.37% | 74.64K 83.76% | ||||
selling and marketing expenses | ||||||||||||
general and administrative expenses | 2.32M - | 302.47K 86.95% | 284.89K 5.81% | 274.31K 3.71% | 187.57K 31.62% | 275.32K 46.78% | 243.03K 11.73% | 300.07K 23.47% | 354.24K 18.05% | 176.99K 50.04% | ||
selling general and administrative expenses | 2.32M - | 302.47K 86.95% | 284.89K 5.81% | 274.31K 3.71% | 187.57K 31.62% | 275.32K 46.78% | 243.03K 11.73% | 300.07K 23.47% | 354.24K 18.05% | 176.99K 50.04% | 265.04K 49.75% | |
research and development expenses | -14.09K - | 41.67K 395.73% | 32.17K 22.79% | |||||||||
other expenses | 101 - | 253 150.50% | 445 75.89% | 445 0% | 10.99K 2,370.11% | 13.18K 19.89% | 68.19K 417.47% | -169.43K - | ||||
cost and expenses | 2.32M - | 302.72K 86.94% | 285.33K 5.74% | 276.60K 3.06% | 199.00K 28.06% | 288.50K 44.98% | 311.22K 7.88% | 338.74K 8.84% | 349.67K 3.23% | 546.56K 56.31% | 312.99K 42.74% | |
operating expenses | 2.32M - | 302.72K 86.94% | 285.33K 5.74% | 274.75K 3.71% | 198.56K 27.73% | 288.50K 45.30% | 311.22K 7.88% | 338.74K 8.84% | 271.77K 19.77% | 253.60K 6.68% | 297.21K 17.19% | |
interest expense | -145.62K - | |||||||||||
ebitda | -2.32M - | -302.47K 86.95% | -284.89K 5.81% | -205.64K 27.82% | -180.46K 12.24% | -275.32K 52.57% | -204.71K 25.65% | -325.56K 59.04% | 102.23K 131.40% | 221.70K 116.87% | -206.79K 193.28% | |
operating income | -2.32M - | -302.72K 86.94% | -285.33K 5.74% | -206.08K 27.78% | -191.45K 7.10% | -288.50K 50.69% | -217.89K 24.48% | -338.74K 55.47% | 89.00K 126.27% | 205.91K 131.37% | -222.57K 208.09% | |
depreciation and amortization | 101 - | 253 150.50% | 445 75.89% | 445 0% | 10.99K 2,370.11% | 13.18K 19.89% | 13.18K 0% | 13.18K 0% | 13.23K 0.40% | 15.79K 19.36% | 15.78K 0.09% | |
total other income expenses net | -1 - | 2 300% | -1 150% | 145.62K 14,562,000% | -2 100.00% | -169.30K 8,464,700% | -169.43K 0.08% | 3 100.00% | ||||
income before tax | -2.32M - | -302.72K 86.94% | -285.33K 5.74% | -206.08K 27.78% | -191.45K 7.10% | -288.50K 50.69% | -72.27K 74.95% | -338.74K 368.72% | -80.30K 76.29% | 36.48K 145.43% | -222.57K 710.16% | |
income tax expense | -1 - | 2 300% | -1 150% | -2 - | 3 - | |||||||
net income | -2.32M - | -302.72K 86.94% | -285.33K 5.74% | -206.08K 27.78% | -191.45K 7.10% | -288.50K 50.69% | -72.27K 74.95% | -338.74K 368.72% | -80.30K 76.29% | 36.48K 145.43% | -222.57K 710.16% | |
weighted average shs out | 83.00M - | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 86.08M 3.72% | 86.48M 0.46% | 86.91M 0.49% | |
weighted average shs out dil | 83.00M - | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 83.00M 0% | 86.08M 3.72% | 86.48M 0.46% | 86.91M 0.49% | |
eps | -0.03 - | -0.00 87.10% | -0.00 5.56% | -0.00 26.47% | -0.00 8.00% | -0.00 52.17% | -0.00 74.29% | -0.00 355.56% | -0.00 78.05% | 0.00 144.44% | -0.00 750% | |
epsdiluted | -0.03 - | -0.00 87.10% | -0.00 5.56% | -0.00 26.47% | -0.00 8.00% | -0.00 52.17% | -0.00 74.29% | -0.00 355.56% | -0.00 78.05% | 0.00 144.44% | -0.00 750% |
All numbers in (except ratios and percentages)